NYSE:BHC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	10,499	N/A	2,685	N/A	3
12/31/2026	10,281	630	2,238	N/A	4
12/31/2025	9,946	523	1,626	N/A	6
12/31/2024	9,625	-46	N/A	N/A	N/A
9/30/2024	9,474	-178	1,009	1,386	N/A
6/30/2024	9,202	-471	911	1,263	N/A
3/31/2024	8,966	-455	785	1,089	N/A
12/31/2023	8,757	-592	760	1,032	N/A
9/30/2023	8,542	-963	893	1,117	N/A
6/30/2023	8,350	-186	-665	-428	N/A
3/31/2023	8,150	-357	-773	-511	N/A
12/31/2022	8,124	-225	-996	-728	N/A
9/30/2022	8,127	254	-1,434	-1,179	N/A
6/30/2022	8,192	43	384	648	N/A
3/31/2022	8,325	-407	648	920	N/A
12/31/2021	8,434	-948	1,143	1,426	N/A
9/30/2021	8,451	-1,170	1,512	1,796	N/A
6/30/2021	8,478	-1,287	1,190	1,488	N/A
3/31/2021	8,042	-1,018	988	1,293	N/A
12/31/2020	8,027	-560	802	1,111	N/A
9/30/2020	8,038	-1,923	641	951	N/A
6/30/2020	8,109	-2,043	899	1,210	N/A
3/31/2020	8,597	-1,888	1,046	1,349	N/A
12/31/2019	8,601	-1,788	1,223	1,501	N/A
9/30/2019	8,498	-616	1,329	1,586	N/A
6/30/2019	8,425	-917	1,386	1,593	N/A
3/31/2019	8,401	-1,619	1,241	1,476	N/A
12/31/2018	8,380	-4,148	1,266	1,501	N/A
9/30/2018	8,422	-3,291	N/A	1,760	N/A
6/30/2018	8,505	-1,640	N/A	1,728	N/A
3/31/2018	8,610	-805	N/A	1,774	N/A
12/31/2017	8,724	2,404	N/A	2,290	N/A
9/30/2017	8,964	1,376	N/A	2,224	N/A
6/30/2017	9,224	-1,143	N/A	2,304	N/A
3/31/2017	9,411	-1,407	N/A	2,484	N/A
12/31/2016	9,674	-2,409	N/A	2,087	N/A
9/30/2016	10,024	-2,280	N/A	2,172	N/A
6/30/2016	10,332	-1,013	N/A	2,360	N/A
3/31/2016	10,644	-764	N/A	2,323	N/A
12/31/2015	10,442	-292	N/A	2,257	N/A
9/30/2015	9,906	596	N/A	2,476	N/A
6/30/2015	9,175	822	N/A	2,336	N/A
3/31/2015	8,484	1,001	N/A	2,302	N/A
12/31/2014	8,200	881	N/A	2,312	N/A
9/30/2014	8,043	502	N/A	1,759	N/A
6/30/2014	7,529	-746	N/A	1,342	N/A
3/31/2014	6,583	-861	N/A	1,271	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BHCは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.8% ) よりも高い成長率であると考えられます。

収益対市場: BHC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BHC今後 3 年以内に収益を上げることが予想されます。

収益対市場: BHCの収益は今後 3 年間で減少すると予想されています (年間-0.1% )。

高い収益成長: BHCの収益は今後 3 年間で減少すると予測されています (年間-0.1% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BHCの自己資本利益率は、3年後には非常に高くなると予測されています ( 71.2 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/02/20 15:26
終値	2025/02/20 00:00
収益	2024/12/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bausch Health Companies Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。42

アナリスト	機関
Douglas Tsao	Barclays
Ardalan Arfaei	BMO Capital Markets Equity Research
Robert Hazlett	BMO Capital Markets U.S. (Historical)

Bausch Health Companies 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target decreased by 7.0% to US$8.83

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Price target decreased by 18% to US$7.79

Price target decreased by 11% to US$8.36

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Recent updates

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Full year 2024 earnings: EPS exceeds analyst expectations

Revenues Working Against Bausch Health Companies Inc.'s (NYSE:BHC) Share Price

Bausch Health Companies Inc., Annual General Meeting, May 13, 2025

Price target decreased by 7.0% to US$8.83

Bausch Health Companies Inc. to Report Q4, 2024 Results on Feb 19, 2025

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors

Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Consensus EPS estimates increase from loss to US$0.11 profit

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?